Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Inc
The main objective of the study is to continue to evaluate the safety and efficacy of YM155.
Each subject will be treated at the dose he/she was receiving at the completion of his/her previous phase I or phase II YM155 study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Completed a Phase I or II YM155 study with at least stable disease and continues to meet the criteria as stated in the previous YM155 study that allows for additional treatment with YM155
Lack of progression based on the most recent radiological imaging, biochemical assessments and/or physical examination
Negative pregnancy test result (females of child-bearing potential)
You may not be if
More than 21 days (or 14 days depending on the study of origin) between the time the last infusion of YM155 was stopped in the previous study and the proposed start of the first infusion in this study
Clareo Health | An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
